X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Belbuca-Generic (buprenorphine) is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is indicated to manage chronic pain severe. It has received CRL from FDA for its resubmitted ANDA.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Belbuca-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Xiromed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
The net proceeds will be utilized for the commercialisation of Exordia (tadalafil), it comprises one of the three main PDE5 inhibitors. It is being evaluated in the treatment of erectile dysfunction.
Lead Product(s): Tadalafil
Therapeutic Area: Psychiatry/Psychology Product Name: Exordia
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Digital Offering, LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 20, 2024
Details:
VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Montelukast VersaFilm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
The agreement aims for the co-development and commercialization of cannabinoid-infused VersaFilm® products, including CBD VersaFilm (cannabinoid), a unique drug opportunity for the treatment of neurodegenerative diseases of the brain.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: CBD VersaFilm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tilray
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 06, 2023
Details:
Rizafilm (rizatriptan) binds with high affinity to human cloned 5-HT1B/1D receptors. It has received FDA approval for the Treatment of acute migraine. It is approved in EU under the name rizaport.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizafilm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gensco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is indicated to manage chronic pain severe enough to require daily, around-the-clock, long-term treatment with an opioid.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Belbuca-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Montelukast VersaFilm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
The agreement aims to investigate the use of IntelGenx’s Montelukast VersaFilm, a leukotriene receptor antagonist, for the treatment of Parkinson’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Montelukast VersaFilm
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karolinska University Hospital
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 25, 2023
Details:
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is indicated to manage chronic pain severe enough to require daily, around-the-clock, long-term treatment with an opioid.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Belbuca-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xiromed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
Rizafilm (rizatriptan) binds with high affinity to human cloned 5-HT1B/1D receptors. It has received FDA approval for the Treatment of acute migraine. It is approved in EU under the name rizaport.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizafilm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
